Flagship peptide screening profile

Mazdutide

A ranked discovery registry is available. No legacy governed direct-evidence relationship has yet been promoted for this profile; the zero below is intentional and must not be interpreted as evidence of absence.

global evidence atlas

Mazdutide research, ranked and separated by purpose

This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

Investigational boundary: Mazdutide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.

51Discoverable PubMed universe

51Ranked screening records

13Research domains

0Governed direct evidence relationships

SearchDomainEvidence class

51 matching records · ranked 2026-09-18

Page 1 of 3

#1Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism · 2026 Oct · PMID 42410325 · DOI 10.1111/dom.71058

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · China and regional evidence · Safety and tolerability · Mechanism and pharmacology

#2Proposed tier Ameta analysisAwaiting human appraisal

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

BMJ medicine · 2026 · PMID 42688617 · DOI 10.1136/bmjmed-2026-003026

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness

#3Proposed tier Ameta analysisAwaiting human appraisal

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Endocrinology, diabetes & metabolism · 2026 Mar · PMID 41787737 · DOI 10.1002/edm2.70187

Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness

#4Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

Diabetes, obesity & metabolism · 2026 Jun · PMID 41804840 · DOI 10.1111/dom.70643

Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability

#5Proposed tier Ameta analysisAwaiting human appraisal

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.

Frontiers in endocrinology · 2025 · PMID 39968298 · DOI 10.3389/fendo.2025.1513641

Weight loss and obesity · Type 2 diabetes and glycemia · Cardiovascular outcomes · Comparative effectiveness

#6Proposed tier Ameta analysisAwaiting human appraisal

Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.

Endocrine · 2024 Oct · PMID 38740695 · DOI 10.1007/s12020-024-03857-6

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology

#7Proposed tier Ameta analysisAwaiting human appraisal

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Cardiology in review · 2026 Feb 19 · PMID 41711462 · DOI 10.1097/CRD.0000000000001209

Weight loss and obesity · Mechanism and pharmacology

#8Proposed tier Ameta analysisAwaiting human appraisal

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

BMJ (Clinical research ed.) · 2026 Jul 8 · PMID 42419792 · DOI 10.1136/bmj-2026-372161

Weight loss and obesity · Comparative effectiveness

#9Proposed tier Ameta analysisAwaiting human appraisal

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.

Metabolism: clinical and experimental · 2024 Dec · PMID 39305981 · DOI 10.1016/j.metabol.2024.156038

Weight loss and obesity · Glucagon and GLP-1 biology · Mechanism and pharmacology · Comparative effectiveness

#10Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in endocrinology · 2024 · PMID 38440786 · DOI 10.3389/fendo.2024.1309118

Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability

#11Proposed tier Ameta analysisAwaiting human appraisal

Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

American journal of therapeutics · 2024 Sep-Oct 01 · PMID 39292847 · DOI 10.1097/MJT.0000000000001756

Weight loss and obesity · Type 2 diabetes and glycemia · Comparative effectiveness

#12Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.

Contemporary clinical trials · 2026 Jan · PMID 41260459 · DOI 10.1016/j.cct.2025.108150

Weight loss and obesity · Type 2 diabetes and glycemia · Comparative effectiveness · Ongoing development

#13Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Nature · 2026 Apr · PMID 41407859 · DOI 10.1038/s41586-025-10026-w

Type 2 diabetes and glycemia · China and regional evidence · Comparative effectiveness

#14Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Nature · 2026 Apr · PMID 41407860 · DOI 10.1038/s41586-025-10031-z

Type 2 diabetes and glycemia · China and regional evidence · Comparative effectiveness

#15Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.

Med (New York, N.Y.) · 2026 May 8 · PMID 41875890 · DOI 10.1016/j.medj.2026.101063

Weight loss and obesity · Type 2 diabetes and glycemia · China and regional evidence

#16Proposed tier Asystematic reviewAwaiting human appraisal

Emerging pharmacotherapies for obesity: A systematic review.

Pharmacological reviews · 2025 Jan · PMID 39952695 · DOI 10.1124/pharmrev.123.001045

Weight loss and obesity · Mechanism and pharmacology

#17Proposed tier Arandomized trialAwaiting human appraisal

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

JAMA · 2026 Aug 4 · PMID 42251595 · DOI 10.1001/jama.2026.8142

Weight loss and obesity · China and regional evidence

#18Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

The lancet. Diabetes & endocrinology · 2026 Aug 21 · PMID 42628555 · DOI 10.1016/S2213-8587(26)00160-9

Weight loss and obesity · Safety and tolerability

#19Proposed tier Arandomized trialAwaiting human appraisal

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

The New England journal of medicine · 2025 Jun 12 · PMID 40421736 · DOI 10.1056/NEJMoa2411528

Weight loss and obesity · China and regional evidence

#20Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Diabetes care · 2024 Jan 1 · PMID 37943529 · DOI 10.2337/dc23-1287

Type 2 diabetes and glycemia · China and regional evidence · Safety and tolerability

#21Proposed tier Arandomized trialAwaiting human appraisal

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

EClinicalMedicine · 2022 Dec · PMID 36247927 · DOI 10.1016/j.eclinm.2022.101691

Weight loss and obesity · Glucagon and GLP-1 biology · China and regional evidence · Safety and tolerability · Mechanism and pharmacology

#22Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Diabetes, obesity & metabolism · 2025 Nov · PMID 40832785 · DOI 10.1111/dom.70040

Weight loss and obesity

#23Proposed tier Arandomized trialAwaiting human appraisal

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

Nature communications · 2022 Jun 24 · PMID 35750681 · DOI 10.1038/s41467-022-31328-x

Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · China and regional evidence · Mechanism and pharmacology

#24Proposed tier Arandomized trialAwaiting human appraisal

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Nature communications · 2023 Dec 14 · PMID 38092790 · DOI 10.1038/s41467-023-44067-4

Weight loss and obesity · China and regional evidence

#25Proposed tier Arandomized trialAwaiting human appraisal

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

EClinicalMedicine · 2021 Sep · PMID 34430840 · DOI 10.1016/j.eclinm.2021.101088

Weight loss and obesity · Glucagon and GLP-1 biology · China and regional evidence · Mechanism and pharmacology

Count reconciliation: 51 discoverable PubMed records match the peptide identity query; 51 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Governed direct evidence relationships.” Domain totals overlap because one publication may inform several questions.

Loading research intelligence

Preparing the structured Flagship evidence library.

Flagship peptide screening profile

Mazdutide

global evidence atlas

Mazdutide research, ranked and separated by purpose

This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

Investigational boundary: Mazdutide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.

51Discoverable PubMed universe

51Ranked screening records

13Research domains

0Governed direct evidence relationships

SearchDomainEvidence class

51 matching records · ranked 2026-09-18

Page 1 of 3

#1Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism · 2026 Oct · PMID 42410325 · DOI 10.1111/dom.71058

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · China and regional evidence · Safety and tolerability · Mechanism and pharmacology

#2Proposed tier Ameta analysisAwaiting human appraisal

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

BMJ medicine · 2026 · PMID 42688617 · DOI 10.1136/bmjmed-2026-003026

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness

#3Proposed tier Ameta analysisAwaiting human appraisal

Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

Endocrinology, diabetes & metabolism · 2026 Mar · PMID 41787737 · DOI 10.1002/edm2.70187

Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology · Comparative effectiveness

#4Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

Diabetes, obesity & metabolism · 2026 Jun · PMID 41804840 · DOI 10.1111/dom.70643

Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability

#5Proposed tier Ameta analysisAwaiting human appraisal

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.

Frontiers in endocrinology · 2025 · PMID 39968298 · DOI 10.3389/fendo.2025.1513641

Weight loss and obesity · Type 2 diabetes and glycemia · Cardiovascular outcomes · Comparative effectiveness

#6Proposed tier Ameta analysisAwaiting human appraisal

Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.

Endocrine · 2024 Oct · PMID 38740695 · DOI 10.1007/s12020-024-03857-6

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · Safety and tolerability · Mechanism and pharmacology

#7Proposed tier Ameta analysisAwaiting human appraisal

Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.

Cardiology in review · 2026 Feb 19 · PMID 41711462 · DOI 10.1097/CRD.0000000000001209

Weight loss and obesity · Mechanism and pharmacology

#8Proposed tier Ameta analysisAwaiting human appraisal

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

BMJ (Clinical research ed.) · 2026 Jul 8 · PMID 42419792 · DOI 10.1136/bmj-2026-372161

Weight loss and obesity · Comparative effectiveness

#9Proposed tier Ameta analysisAwaiting human appraisal

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.

Metabolism: clinical and experimental · 2024 Dec · PMID 39305981 · DOI 10.1016/j.metabol.2024.156038

Weight loss and obesity · Glucagon and GLP-1 biology · Mechanism and pharmacology · Comparative effectiveness

#10Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in endocrinology · 2024 · PMID 38440786 · DOI 10.3389/fendo.2024.1309118

Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability

#11Proposed tier Ameta analysisAwaiting human appraisal

Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

American journal of therapeutics · 2024 Sep-Oct 01 · PMID 39292847 · DOI 10.1097/MJT.0000000000001756

Weight loss and obesity · Type 2 diabetes and glycemia · Comparative effectiveness

#12Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.

Contemporary clinical trials · 2026 Jan · PMID 41260459 · DOI 10.1016/j.cct.2025.108150

Weight loss and obesity · Type 2 diabetes and glycemia · Comparative effectiveness · Ongoing development

#13Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Nature · 2026 Apr · PMID 41407859 · DOI 10.1038/s41586-025-10026-w

Type 2 diabetes and glycemia · China and regional evidence · Comparative effectiveness

#14Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Nature · 2026 Apr · PMID 41407860 · DOI 10.1038/s41586-025-10031-z

Type 2 diabetes and glycemia · China and regional evidence · Comparative effectiveness

#15Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.

Med (New York, N.Y.) · 2026 May 8 · PMID 41875890 · DOI 10.1016/j.medj.2026.101063

Weight loss and obesity · Type 2 diabetes and glycemia · China and regional evidence

#16Proposed tier Asystematic reviewAwaiting human appraisal

Emerging pharmacotherapies for obesity: A systematic review.

Pharmacological reviews · 2025 Jan · PMID 39952695 · DOI 10.1124/pharmrev.123.001045

Weight loss and obesity · Mechanism and pharmacology

#17Proposed tier Arandomized trialAwaiting human appraisal

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

JAMA · 2026 Aug 4 · PMID 42251595 · DOI 10.1001/jama.2026.8142

Weight loss and obesity · China and regional evidence

#18Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

The lancet. Diabetes & endocrinology · 2026 Aug 21 · PMID 42628555 · DOI 10.1016/S2213-8587(26)00160-9

Weight loss and obesity · Safety and tolerability

#19Proposed tier Arandomized trialAwaiting human appraisal

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

The New England journal of medicine · 2025 Jun 12 · PMID 40421736 · DOI 10.1056/NEJMoa2411528

Weight loss and obesity · China and regional evidence

#20Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Diabetes care · 2024 Jan 1 · PMID 37943529 · DOI 10.2337/dc23-1287

Type 2 diabetes and glycemia · China and regional evidence · Safety and tolerability

#21Proposed tier Arandomized trialAwaiting human appraisal

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

EClinicalMedicine · 2022 Dec · PMID 36247927 · DOI 10.1016/j.eclinm.2022.101691

Weight loss and obesity · Glucagon and GLP-1 biology · China and regional evidence · Safety and tolerability · Mechanism and pharmacology

#22Proposed tier Arandomized trialAwaiting human appraisal

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Diabetes, obesity & metabolism · 2025 Nov · PMID 40832785 · DOI 10.1111/dom.70040

Weight loss and obesity

#23Proposed tier Arandomized trialAwaiting human appraisal

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

Nature communications · 2022 Jun 24 · PMID 35750681 · DOI 10.1038/s41467-022-31328-x

Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · China and regional evidence · Mechanism and pharmacology

#24Proposed tier Arandomized trialAwaiting human appraisal

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Nature communications · 2023 Dec 14 · PMID 38092790 · DOI 10.1038/s41467-023-44067-4

Weight loss and obesity · China and regional evidence

#25Proposed tier Arandomized trialAwaiting human appraisal

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.

EClinicalMedicine · 2021 Sep · PMID 34430840 · DOI 10.1016/j.eclinm.2021.101088

Weight loss and obesity · Glucagon and GLP-1 biology · China and regional evidence · Mechanism and pharmacology